5,710 Shares in Omnicell, Inc. (NASDAQ:OMCL) Bought by Everence Capital Management Inc.

Everence Capital Management Inc. purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,710 shares of the company’s stock, valued at approximately $249,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its position in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares during the period. GAMMA Investing LLC grew its position in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. EntryPoint Capital LLC grew its position in shares of Omnicell by 121.2% in the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after purchasing an additional 1,345 shares during the period. CWM LLC grew its position in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in shares of Omnicell in the second quarter valued at about $104,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Price Performance

Shares of OMCL stock opened at $41.10 on Wednesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The firm’s 50-day moving average is $43.21 and its two-hundred day moving average is $34.52. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $45.84. The company has a market capitalization of $1.89 billion, a PE ratio of -89.35, a price-to-earnings-growth ratio of 45.31 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. During the same period in the previous year, the firm earned $0.29 earnings per share. Omnicell’s quarterly revenue was down 7.4% compared to the same quarter last year. Analysts predict that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on OMCL shares. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Benchmark reissued a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company raised their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, Bank of America raised their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.